Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

BACKGROUND: We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). METHODS: COUGH-1 (NCT03449134) and COUGH-2 (NCT03449147) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Muccino, David R., Morice, Alyn H., Birring, Surinder S., Dicpinigaitis, Peter V., Pavord, Ian D., Assaid, Christopher, Kleijn, Huub Jan, Hussain, Azher, La Rosa, Carmen, McGarvey, Lorcan, Smith, Jaclyn A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Study Protocols
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682670/
https://www.ncbi.nlm.nih.gov/pubmed/33263037
http://dx.doi.org/10.1183/23120541.00284-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682670/
https://www.ncbi.nlm.nih.gov/pubmed/33263037
http://dx.doi.org/10.1183/23120541.00284-2020

Ejemplares similares